UroAlert - GU Oncology Weekly

February 12, 2026

Videos

Peer-to-Peer Clinical Conversations

Real-World Experience With the Expanded Access Program for 89Zr-Girentuximab PET in Small Renal Masses - R. Jonathan Henderson

Jonathan Henderson

Zachary Klaassen hosts Jonathan Henderson to discuss his experience with the Expanded Access Program for [89Zr]Zr-girentuximab PET imaging for small renal masses.

Phase III CAPItello-281 Trial Results for mHSPC with PTEN Loss - Karim Fizazi

Karim Fizazi

Neeraj Agarwal speaks with Karim Fizazi about the CAPItello-281 phase three trial examining capivasertib combined with abiraterone in metastatic hormone-sensitive prostate cancer patients with PTEN deficiency.

Beyond the Abstracts

Lipid Metabolism of Clear Cell Renal Cell Carcinoma Predicts Survival and Affects Intratumoral CD8 T Cells - Beyond the Abstract

Impact on Oncological Outcomes of Detrusor Muscle Absence in pTaHG Urothelial Carcinoma of the Bladder? the End of the "Jump" of the Lamina Propria Layer Myth - Beyond the Abstract

Conference Coverage

SUO 2025: Costs of Care and Oncologic Outcomes Associated with Blue Light Cystoscopy in an Equal Access Setting: Results from the BRAVO Study

SUO 2025: Precystectomy ctDNA Burden is Predictive of Poor Oncological Outcomes

SUO 2025: LITESPARK-004: 5-Year Follow-up of the Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms

ESMO 2025: Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear Cell Renal Cell Carcinoma: a Multicentre Single-Arm Phase II Trial (RENALUT)

ESMO 2025: Disitamab Vedotin plus Tislelizumab as Nephron-Sparing Therapy for High-Risk Upper Tract Urothelial Carcinoma: The Phase II DISTINCT-I Trial

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.

Molecular characterization of non-muscle invasive tumor from N-methyl-N-nitrosourea (MNU)-induced urothelial carcinoma in a rat model reveals hallmarks of both luminal and basal subtypes.

ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only NMIBC

The challenge of bladder preservation in muscle invasive bladder cancer: key concepts and future directions.

Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: a systematic review.

Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.

Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?.

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

Understanding Bladder Cancer Screening Limits Through Comparative Modeling: The Maximum Clinical Incidence Reduction (MCLIR) Methodology.

ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer.

Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.

Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics - Beyond the Abstract

T Cell Subsets of Urine-Derived Lymphocytes (UDLs) Serve as an Indicator of TILs and Reflect Immunological Sex Differences in Bladder Cancer - Beyond the Abstract

Penile & Urethral Cancers

Current diagnostics and treatment of penile cancer.

Decoding the Cellular Heterogeneity and Malignant Progression of Human Penile Squamous Cell Carcinoma by Single-Cell RNA Sequencing.

Renal Cancer

Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.

Surgical Management of Nonmetastatic Renal Cell Carcinoma with Inferior Vena Cava Thrombus: A Systematic Review and Network Meta-analysis.

Deep Learning Identification of Clear Cell Renal Cell Carcinoma on MR Imaging.

Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study.

Percutaneous Biopsy and Recurrence Risk in Stage 1 Renal Cancer: A Propensity Score-Matched Cohort Study.

Real-World Outcomes of First-Line Immune-Based Combination Therapies in Bone-Metastatic Clear Cell Renal Cell Carcinoma.

The use of computed tomography during follow-up after ablation of cT1 renal cell carcinoma: evidence for overuse.

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

Racial and socioeconomic disparities from time of diagnosis to treatment for small renal masses.

Telomere-based Risk Model for Prognosis Prediction in Clear Cell Renal Cell Carcinoma.

Impact of Proton Pump Inhibitor Use on the Efficacy of IO-IO Versus IO-TKI Therapy in Metastatic Renal Cell Carcinoma.

Kidney-Sparing Treatments for Local Recurrence in Renal Cell Tumours after Partial Nephrectomy or Focal Therapy: A Systematic Review - Beyond the Abstract

Prostate Cancer

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Biochemical control and 2-year tolerability following stereotactic body radiotherapy for localized prostate cancer: a multicenter study in Spain.

Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.

Transperineal Versus Transrectal Biopsy for Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).

Mechanistic Language Modeling and Oxygenated 3D Screening Reveal Berberine and Enzalutamide Synergy in Resistant Prostate Cancer.

Automated evaluation of organ sparing in prostate stereotactic body radiation therapy using dose-gradient metrics.

Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized Trials.

Nurses' Perspectives of a Digital Supportive Intervention When Caring for Patients During Radiotherapy for Prostate Cancer: A Qualitative Study.

Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study.

Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Time-Dependent Analysis of Reconstructed Individual Patient Data From the PEACE-3 Trial.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.

Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study.

Patient awareness and perspectives regarding the value of focal therapy for localized prostate cancer: A cross-sectional study.

The Impact of Race on Oncological Outcomes in Patients with an Initial Negative Prostate Biopsy: Results from a Contemporary U.S. Cohort.

Statin use and outcomes in advanced prostate cancer:Secondary analysis of the SPARTAN trial.

Predicting Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Model Development and Evaluation in an International Cohort Study.

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer.

Challenges in analyzing real-world evidence: analysis of androgen deprivation therapy use for prostate cancer in the REASSURE study.

Radio-pathomic maps of histo-morphometric features trained with whole mount prostate histology distinguish prostate cancer on MP-MRI.

Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy.

Evaluation of the appropriateness of PSA test prescription as opportunistic screening for prostate cancer in a metropolitan area of Northern Italy: Data from of the Agency for Health Protection of the Metropolitan Area of Milan.

Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.

Shifting the paradigm of PSMA delivery in prostate cancer for internal radiotherapy: An innovative ultrasound-mediated approach.

Tolerability and the Accelerome: Open-Source Wrist Accelerometry Relates to Symptom Burden in Androgen Ablated Older Men with Prostate Cancer.

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization.

Measuring the Impact of Common Prostate Cancer Survivorship Conditions with Health Utilities.

Prostate Cancer Outcomes in Immunocompromised Patients: A Systematic Review and Meta-analysis - Beyond the Abstract

Artificial Intelligence in Diagnostic, Prognostic, and Predictive Genomic Biomarkers for Prostate Cancer: Ready for Prime Time? - Beyond the Abstract

Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [18F]PSMA-1007 PET/CT and [18F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management - Beyond the Abstract

Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate after Radical Prostatectomy in Men with High-risk Localized Prostate Cancer - Beyond the Abstract

Rechallenge and Extended [177Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer - Beyond the Abstract

Upper Tract Tumors

Venous invasion in upper tract urothelial carcinoma: Diagnostic features and oncologic outcomes.

Risk of Recurrence and Progression after Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma - Beyond the Abstract

Testicular Cancer

Anxiety, Depression, and Suicidality Among Testicular Cancer Survivors.

Semen Cryopreservation in Testicular Cancer: Before or After Orchidectomy?

Deterioration in Physical Fitness and Changes in Body Composition After Cisplatin-Based Chemotherapy for Metastatic Testicular Cancer.

Incremental dose-response effect of age on mortality in non-seminoma testis cancer patients.

The Promise of Mindfulness-Based Interventions: A Stress-Reduction Strategy for Testicular Cancer Survivors' Health-Related Quality of Life.

Second edition ICCR dataset for testicular germ cell tumours: a reporting guide for histopathological diagnosis of orchiectomy specimens.

Can Novel Biomarkers Augment Traditional Surveillance Paradigms in Early-Stage Testicular Germ Cell Tumors? a Case Study in Pre-Clinical Relapse Detection Using a Combination Micro-RNA-371a-3p and 372-3p Assay - Beyond the Abstract

Adrenal Diseases

Treatment of non-muscle-invasive bladder cancer.

Results from the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC